MannKind Deal History & Licensing Activity
MannKind is a biotech. Over the past three years, MannKind has been involved in 1 licensing and acquisition transaction, with a primary focus on Other (2 deals). The company currently has 5 active clinical trials, primarily in Metabolic.
Deals (12mo)
1
Active Trials
5
Top Modality
Other
Focus Area
Metabolic
MannKind Recent Deal Activity
Licensing, acquisition, and partnership transactions involving MannKind in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| scPharmaceuticals subcutaneous cardiology/diuresis products | scPharmaceuticals | Other | Unknown | acquisition | Jun 2, 2026 |
MannKind Pipeline Focus
Therapeutic areas and modalities where MannKind is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
MannKind Clinical Pipeline
MannKind has 5 active clinical trials across 3 development phases.
1
Not Applicable
2
Phase 1
2
Phase 2
See How Your Asset Matches MannKind's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Metabolic assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About MannKind Licensing & Deal Activity
MannKind is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, MannKind ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for MannKind include Metabolic (3 deals and trials), and Cardiovascular (2 deals and trials). In terms of modality, MannKind has shown particular interest in other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for MannKind and 850+ other biopharma companies. Use our Solidus to benchmark your asset against MannKind's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.